Helicos Reports $1.1M in Q3 Revenue; Rules Out Company Sale for Now as Prospects Improve | GenomeWeb

Helicos BioSciences said this week that, for now, it no longer considers a sale of the company as its business prospects and market valuation have been improving.

The company, which made the announcement along with its third-quarter earnings release, also indicated that it is weighing price reductions for its instrument and plans to introduce new reagent kits.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.